Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

Sedana Medical presents at ESICM

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium at ESICM Lives 2021, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation will al…

Sedana Medical receives approval in Germany

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany.

Sedana Medical presenting at ISICEM

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will host a symposium at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels on August 31-September 3, 2021, where the full details…

Sedana Medical's Sedaconda study published in the Lancet

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine.

Sedana Medical receives approval in France

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in France.

Sedana Medical receives approval for European dossier

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation o…

Sedana Medical announces positive FDA interaction

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has completed a successful End of phase II meeting with the US Food and Drug Administration (FDA). The FDA accepted Sedana Medical's proposals for phase III program, inc…

Sedana Medical receives QMS MDR approval

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received an approval for its quality system (QMS) according to the EU Medical Device Regulation (MDR) 2017/745. The approval means that Sedana Medical's Class I medi…

Sedana Medical's Sedaconda study awarded at DGIIN & ÖGIAIN

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's pivotal phase III study Sedaconda (SED001) has been named one of the three best posters at the 52[nd] intensive care conference DGIIN & ÖGIAIN 16–18 June 2021.

Sedana Medical appoints Johannes Doll as new CEO

Regulatory

Sedana Medical’s (publ) (SEDANA: FN Stockholm) Board of Directors has appointed Johannes Doll as the company’s new CEO. Johannes Doll will take office no later than November 1, 2021, succeeding Christer Ahlberg, who, as announced previously, will lea…

Bulletin from the annual general meeting in Sedana Medical AB

Regulatory

Today, May 10, 2021, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In order to counteract the spreading of the corona virus, the general meeting was held only through advance voting (so-called postal voting)…

Notice of Annual General Meeting in Sedana Medical AB (publ)

Regulatory

The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting to be held on Monday 10 May 2021. In order counteract the spreading of the corona virus, the board of directors of the co…